TAmiRNA to present a novel assay for Genome-Scale Analysis and Absolute Quantitation of MicroRNAs across Sample Types and Species at RNA Biology Microsymposium

Biotech and diagnostic innovator TAmiRNA will be a significant presence at the upcoming 16th Microsymposium on RNA Biology organised by the Austrian bioresearch community.

TAmiRNA is a long term supporter and current sponsor of the event. It will also present the 2022 meeting with insights on its innovative technology for small RNA sequencing, miND ( MicroRNA Next-Generation-Sequencing Discovery Assay).

MicroRNA Next-Generation-Sequencing Discovery Assay (miND)

On the afternoon of Day Two of the symposium (April 7), TAmiRNA Senior Scientist Dr. Kseniya Khamina will deliver a presentation A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) for Genome-Scale Analysis and Absolute Quantitation of MicroRNAs across Sample Types and Species.

Her presentation will form part of Session 4 on ‘Development and imaging’ (1410-1600 hrs CET).

Control with miND spike-ins

TAmiRNA developed a novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data.  The miND assay consists of miND spike-in that is added to a sample during the NGS library preparation according to the protocol from RealSeq Biosciences and miND bioinformatics pipeline that automatically process FASTQ or BAM files and normalise the generated data based on the miND spike-in read counts. The analysed NGS data are presented as a simple and interactive report that includes reads classification, microRNA mapping statistics and absolute concentration for each microRNA (molecules/µL of input RNA). miND spike-in serves as a quality control for NGS library preparations and ensures comparability of data across independent NGS experiments through absolute normalisation.

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis and prognosis of disease, and as companion diagnostic tests to support treatment decisions.

For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898 and from TransBioLine project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

More information available at: www.tamirna.com

About Microsymposium on RNA Biology 2022

The Microsymposium on RNA Biology is an international conference that brings together young scientists, junior and senior group leaders, and company representatives from all over the world to present and discuss their latest findings in the exciting field of small RNAs. These play key roles in all three eukaryotic kingdoms in the silencing of gene expression with central functions in the repression of viruses and transposons, shaping organismal development, physiological processes and human diseases, such as cancer.

The Microsymposium was founded in 2005 and has established itself as the major small RNA meeting in Europe. It is organized by the four research institutions IMBA, IMP, GMI and the Max Perutz Labs as well as by the RNA community of the Vienna BioCenter.

The 16th Microsymposium is a three-day event opening April 5 2022 at the IMP and IMBA institutes on the Vienna BioCenter campus.

To strengthen the focus on the new generation of scientists, the Microsymposium invites—besides established leaders in the field— postdocs and PhD students (selected from submitted poster abstracts) as speakers.

The event is primarily organized by the Austrian Academy of Science (OAW) Institute for Molecular Biotechnology (IMBA) with further information at: https://www.oeaw.ac.at/imba/seminars-events/microsymposium


Click on miRNA NGS Discovery pipeline – miND for further insights on TAmiRNA’s bioinformatic research pipeline.
Click on A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) for Genome-Scale Analysis and Absolute Quantitation of Circulating MicroRNA Biomarkers to access original research paper lead-authored by Dr. Kseniya Khamina.

TAmiRNA senior scientist, Dr. Kseniya Khamina, will present insights on miND technology.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.